Celiac.com 04/24/2015 - Dr. Falk Pharma and Zedira recently announced the start of phase I clinical trials for the drug candidate ZED1227, a direct acting inhibitor of tissue transglutaminase.
In 2011, Dr. Falk Pharma licensed the rights for ZED1227 in Europe and took charge of pre-clinical and clinical development of the new drug. The license agreement secured Zedira an upfront payment and further milestone payments as well as royalties. The rights outside Europe are jointly owned by the partners.
The project receives additional support through a grant from the German Ministry for Education and Research within the Cluster of Excellence program “Ci3-Cluster for Individualized Immune Intervention."